193 related articles for article (PubMed ID: 18421566)
1. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis.
Zheng Y; Zhou H; Fong-Yee C; Modzelewski JR; Seibel MJ; Dunstan CR
Clin Exp Metastasis; 2008; 25(5):559-67. PubMed ID: 18421566
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis.
Ooi LL; Zheng Y; Zhou H; Trivedi T; Conigrave AD; Seibel MJ; Dunstan CR
Bone; 2010 Oct; 47(4):795-803. PubMed ID: 20638491
[TBL] [Abstract][Full Text] [Related]
4. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
5. Bone resorption and bone metastasis risk.
Mathis KM; Sturgeon KM; Winkels RM; Wiskemann J; De Souza MJ; Schmitz KH
Med Hypotheses; 2018 Sep; 118():36-41. PubMed ID: 30037612
[TBL] [Abstract][Full Text] [Related]
6. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
7. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
[TBL] [Abstract][Full Text] [Related]
8. Tracking the Progression of Osteolytic and Osteosclerotic Lesions in Mice Using Serial In Vivo μCT: Applications to the Assessment of Bisphosphonate Treatment Efficacy.
Campbell GM; Tower RJ; Damm T; Kneissl P; Rambow AC; Schem C; Tiwari S; Glüer CC
J Bone Miner Res; 2018 Mar; 33(3):410-418. PubMed ID: 29044710
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.
Yi B; Williams PJ; Niewolna M; Wang Y; Yoneda T
Cancer Res; 2002 Feb; 62(3):917-23. PubMed ID: 11830552
[TBL] [Abstract][Full Text] [Related]
10. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer Treat Rev; 1999 Oct; 25(5):293-9. PubMed ID: 10544073
[TBL] [Abstract][Full Text] [Related]
11. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.
Biswas S; Nyman JS; Alvarez J; Chakrabarti A; Ayres A; Sterling J; Edwards J; Rana T; Johnson R; Perrien DS; Lonning S; Shyr Y; Matrisian LM; Mundy GR
PLoS One; 2011; 6(11):e27090. PubMed ID: 22096521
[TBL] [Abstract][Full Text] [Related]
12. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.
Taube T; Elomaa I; Blomqvist C; Beneton MN; Kanis JA
Bone; 1994; 15(2):161-6. PubMed ID: 8086233
[TBL] [Abstract][Full Text] [Related]
13. Anti-c-fms Antibody Prevents Osteoclast Formation and Bone Resorption in Co-Culture of Osteoblasts and Osteoclast Precursors In Vitro and in Ovariectomized Mice.
Nara Y; Kitaura H; Ogawa S; Shen WR; Qi J; Ohori F; Noguchi T; Marahleh A; Pramusita A; Kinjo R; Mizoguchi I
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854340
[TBL] [Abstract][Full Text] [Related]
14. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
15. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
16. Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone.
Zheng Y; Zhou H; Modzelewski JR; Kalak R; Blair JM; Seibel MJ; Dunstan CR
Cancer Res; 2007 Oct; 67(19):9542-8. PubMed ID: 17909065
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
Peng S; Liu XS; Zhou G; Li Z; Luk KD; Guo XE; Lu WW
J Bone Miner Res; 2011 Jun; 26(6):1272-82. PubMed ID: 21611968
[TBL] [Abstract][Full Text] [Related]
20. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone.
Ouellet V; Tiedemann K; Mourskaia A; Fong JE; Tran-Thanh D; Amir E; Clemons M; Perbal B; Komarova SV; Siegel PM
Am J Pathol; 2011 May; 178(5):2377-88. PubMed ID: 21514448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
